Cencora Reports Strong Q2 Earnings, Positive Opioid Litigation Update, and Increased Debt for OneOncology Acquisition
COR is trading near its 52-week low of $244.82 (3.3% above the low) on elevated volume (3.8× avg).
Summary
Cencora reported strong Q2 fiscal 2026 results with substantial revenue and EPS growth, driven by strategic acquisitions and strong segment performance, while also detailing a positive legal development in the Maryland opioid case.
Key Events · Earnings and Guidance · COR
-
Strong Q2 Fiscal 2026 Financial Performance
Revenue increased by 3.8% to $78.36 billion for the quarter and 4.7% to $164.29 billion for the six-month period. Net income attributable to Cencora, Inc. surged to $1.64 billion for the quarter and $2.20 billion for the six-month period, with diluted EPS reaching $8.40 and $11.27, respectively. This includes a $1.1 billion gain on the remeasurement of an equity method investment related to the OneOncology acquisition.
-
Significant OneOncology Acquisition Details
The company completed the acquisition of a majority interest in OneOncology on February 2, 2026, for a total fair value consideration of $7.39 billion, including $4.65 billion in cash. This strategic acquisition significantly expanded the U.S. Healthcare Solutions segment.
-
Increased Long-Term Debt for Acquisitions
Long-term debt increased from $7.54 billion as of September 30, 2025, to $12.18 billion as of March 31, 2026, primarily to finance the OneOncology acquisition. The company also increased its multi-currency revolving credit facility to $5.5 billion.
-
Positive Development in Maryland Opioid Litigation
The Maryland Supreme Court vacated a judgment against a subsidiary in an opioid public nuisance case on April 24, 2026, and remanded it for further proceedings, a favorable outcome for the company. The overall accrued opioid litigation liability remains at $4.3 billion.
Analysis · COR · Trade & Services
Cencora's Q2 fiscal 2026 10-Q details robust financial performance, with significant revenue and EPS growth driven by strategic acquisitions and strong segment performance. The report provides the full financial context for the previously announced Q2 earnings and raised guidance. A key positive development is the Maryland Supreme Court vacating a judgment against a subsidiary in an opioid public nuisance case, reducing a potential liability. The company also recorded an $86.8 million credit from a shareholder derivative lawsuit settlement. While long-term debt increased significantly to fund the $7.3 billion OneOncology acquisition, and cash flow from operations shifted to a net use, these are largely tied to strategic investments. The $165.7 million goodwill impairment is related to a business held for sale. This strong performance and positive legal news come as the stock trades near its 52-week lows, potentially indicating an undervaluation by the market.
At the time of this filing, COR was trading at $252.82 on NYSE in the Trade & Services sector, with a market capitalization of approximately $48.8B. The 52-week trading range was $244.82 to $377.54. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.